What is SynergEyes?
SynergEyes specializes in the development and distribution of advanced hybrid contact lens technology. Their product portfolio features a range of specialty lenses, including SynergEyes iD, Duette, UltraHealth, and scleral lenses, meticulously engineered to provide superior vision clarity and comfort. These offerings are particularly beneficial for individuals managing irregular corneas or conditions like keratoconus. The company primarily serves eye care professionals and patients seeking bespoke vision correction solutions, positioning itself at the forefront of therapeutic contact lens innovation.
How much funding has SynergEyes raised?
SynergEyes has raised a total of $42.2M across 7 funding rounds:
Series B
$16M
Series C
$13.3M
Debt
$5M
Private Equity
$2M
Private Equity
$3.5M
Debt
$1M
Debt
$1.4M
Series B (2006): $16M with participation from Windward Ventures, Innocal Venture Capital, De Novo Ventures, Delphi Ventures, and Alloy Ventures
Series C (2009): $13.3M led by Windward Ventures, Delphi Ventures, and Alloy Ventures
Debt (2011): $5M supported by Oxford Finance Corporation
Private Equity (2014): $2M, investors not publicly disclosed
Private Equity (2017): $3.5M backed by De Novo Ventures and Delphi Ventures
Debt (2020): $1M with participation from PPP
Debt (2021): $1.4M led by PPP
Key Investors in SynergEyes
De Novo Ventures
De Novo Ventures is a venture capital firm specializing in early-stage investments within the medical device and biotechnology sectors, bringing extensive experience in funding innovative healthcare solutions.
Delphi Ventures
Delphi Ventures is a venture capital firm with a two-decade focus on early-stage medical device and biotechnology investments, having supported over 150 companies with significant capital.
Oxford Finance Corporation
Oxford Finance Corporation is a specialty finance firm established in 2002, providing flexible financial solutions to healthcare and life sciences companies globally.
What's next for SynergEyes?
With the recent infusion of major strategic capital, SynergEyes is poised for accelerated growth and enhanced market penetration. The company's focus on developing specialized contact lenses for challenging eye conditions indicates a strategic direction towards addressing unmet needs within the optometry and ophthalmology fields. Future endeavors will likely involve expanding their product development pipeline, scaling manufacturing capabilities, and broadening their distribution network to reach a wider patient base. Continued investment in research and development will be crucial for maintaining their competitive edge in the advanced vision correction market.
See full SynergEyes company page
